Immunovant (IMVT) investor relations material

Strategic focus and product pipeline

• Pursuing a broad anti-FcRn strategy with IMVT-1402, targeting autoantibody-driven diseases and aiming for best-in-class efficacy and convenience across multiple indications.

• IMVT-1402 is positioned as a potential first- and best-in-class product, with robust IgG lowering, favorable safety, and simple autoinjector delivery.

• Ongoing and planned registrational trials span Graves' disease, Sjögren's disease, difficult-to-treat rheumatoid arthritis, CIDP, MG, and CLE, addressing over 600,000 US patients.

• Strong patent protection extends to 2043, supporting long-term commercial potential.

• Cash balance of ~$600 million as of June 2025 provides runway through key clinical readouts.

Clinical evidence and differentiation

• Deeper IgG reduction with anti-FcRn therapy correlates with improved clinical outcomes across multiple autoimmune indications.

• IMVT-1402 and batoclimab demonstrate best-in-class IgG reductions (up to ~80%), outperforming competitors in cross-trial comparisons.

• Phase 3 batoclimab data in MG showed highest MG-ADL reduction and minimal symptom expression rates among global trials.

• Batoclimab CIDP Phase 2b data showed 84% response rate in patients with ≥70% IgG reduction, informing IMVT-1402 trial design.

• IMVT-1402 is delivered via a user-friendly, market-proven autoinjector, supporting at-home or HCP administration.

Market opportunity and unmet need

• Large total addressable market with 20+ indications in development across the anti-FcRn class, including neurology, endocrinology, rheumatology, dermatology, and renal diseases.

• Graves' disease: ~880K US prevalence, with ~330K relapsed, uncontrolled, or intolerant to ATDs, and ~20K annual incident second-line patients.

• Myasthenia gravis: 59K–116K US patients, with 35% not well-controlled on standard of care and high rates of residual symptoms on current therapies.

• CIDP: 58K US patients, with 30–50% inadequately controlled on existing therapies and high demand for improved response and convenience.

• D2T RA: 5–20% of 1.5M US RA patients are difficult-to-treat, representing a 70K addressable population needing new options.

• Sjögren's disease: 290K US prevalence, no approved therapies, and 90K addressable patients with moderate-to-severe disease.

• CLE: 153K US prevalence for SCLE and CCLE, with up to 50% non-responders to current therapies and no novel treatments in over 50 years.